01Define the system and the barrier question

USP’s public package-integrity introduction links leakage limits with protection of sterility and relevant physicochemical properties. It treats integrity assurance as a product-life-cycle question rather than a one-time visual judgement of the cap.USP — Package integrity evaluation (opens in a new tab)

A closure can appear normal while a small defect remains unresolved. Conversely, an unusual appearance is a reason to investigate, not a complete measurement of leakage rate.

The package description should include the components and assembly that were actually tested. Evidence for a different stopper, vial or seal arrangement cannot be transferred automatically.

02Understand what the selected test detects

FDA’s integrity guidance describes several possible physical, chemical and microbiological approaches, with validation and product compatibility central to their use. The guidance concerns defined stability-protocol applications, not unrestricted replacement of every sterility test.FDA — Container and closure integrity in stability protocols (opens in a new tab)

Pressure- or vacuum-based methods assess a pressure-related response associated with leakage under the test conditions. Tracer methods investigate passage of a selected substance. A microbial challenge investigates ingress under its particular exposure conditions.

Those measurements are connected with barrier performance in different ways. A gas leak rate, a tracer-detection result and a microbial-ingress observation should not be treated as identical units.

The final result should identify the technique and its interpreted limit. A generic “seal passed” statement can conceal which failure modes were examined.

03Use known defects without assuming every defect behaves alike

Simonetti and Amari compared vacuum decay, dye ingress and high-voltage testing in prefilled glass syringes with defined simulated defects. Their study used different defect locations and constructions, and found different performance across the tested approaches.Simonetti and Amari — Comparison of prefilled-syringe integrity methods (opens in a new tab)

The study supports evaluating both the test and the defect model. Its method ranking should not be universalised to every vial, formulation or package geometry.

For an original comparison, two artificial defects with the same nominal opening diameter may have different path lengths or positions relative to the contents. Treating them as equivalent challenges solely because their diameters match can miss relevant differences.

Nguyen and colleagues demonstrated an indirect relationship between vacuum-decay testing and previously characterised leakage standards. Their work illustrates how physical measurements can be linked with microbial-barrier evidence rather than assumed to mean the same thing.Nguyen and colleagues — Relating vacuum-decay measurements to microbial-barrier evidence (opens in a new tab)

Keep positive controls, intact controls and sample results distinguishable. A valid instrument response to a control supports test performance; it does not determine the outcome of each unexamined package.

04Keep the conclusion within the tested life-cycle conditions

USP’s public method-selection chapter identifies package development, manufacturing and shelf-life assessments as distinct life-cycle phases. Evidence from one phase does not automatically cover all later stresses or time points.USP — Package integrity method selection across the life cycle (opens in a new tab)

A package assessed immediately after assembly has not thereby been demonstrated to remain unchanged after transport or storage. Similarly, evidence on an unopened package does not automatically cover a package after it has been accessed.

The useful conclusion states what barrier performance was demonstrated and under which conditions. It should not become a claim that the contents are chemically correct, free of endotoxin or suitable for human administration.